PD-1/PD-L1 Inhibitors for Non–Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management

Programmed cell death protein 1 receptor and programmed cell death ligand 1 (PD-L1) inhibitors are immune checkpoint inhibitors (ICIs) that provide a survival benefit for select patients with advanced non–small cell lung cancer (NSCLC). Nivolumab, pembrolizumab, and atezolizumab are second-line ther...

Descripción completa

Detalles Bibliográficos
Autor principal: Davies, Marianne J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522661/
https://www.ncbi.nlm.nih.gov/pubmed/33014515
http://dx.doi.org/10.6004/jadpro.2019.10.2.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522661/
https://www.ncbi.nlm.nih.gov/pubmed/33014515
http://dx.doi.org/10.6004/jadpro.2019.10.2.11

Ejemplares similares